as 05-09-2025 9:56am EST
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Founded: | 2018 | Country: | United States |
Employees: | N/A | City: | SAN FRANCISCO |
Market Cap: | 679.9M | IPO Year: | N/A |
Target Price: | $8.20 | AVG Volume (30 days): | 3.2M |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.03 | EPS Growth: | N/A |
52 Week Low/High: | $1.54 - $3.97 | Next Earning Date: | 05-07-2025 |
Revenue: | $10,957,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | 75.73% | Revenue Growth (next year): | 440.21% |
NUVB Breaking Stock News: Dive into NUVB Ticker-Specific Updates for Smart Investing
Insider Monkey
6 hours ago
Zacks
2 days ago
Business Wire
2 days ago
Business Wire
8 days ago
Business Wire
17 days ago
Insider Monkey
23 days ago
Insider Monkey
a month ago
Insider Monkey
a month ago
The information presented on this page, "NUVB Nuvation Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.